TY - JOUR
T1 - Total body irradiation in acute myeloid leukemia and chronic myelogenous leukemia
T2 - influence of dose and dose-rate on leukemia relapse
AU - Scarpati, Daniele
AU - Frassoni, Francesco
AU - Vitale, Vito
AU - Corvo, Renzo
AU - Franzone, Paola
AU - Barra, Salvina
AU - Guenzi, Marina
AU - Orsatti, Marco
PY - 1989
Y1 - 1989
N2 - From June 1981 to March 1987, 106 patients-59 with acute myeloid leukemia (AML) and 47 with chronic myelogenous leukemia (CML)-were treated with Cyclophosphamide 60 mg/kg X2 d and total body irradiation (TBI-990 cGy/3fr/3d described dose) before allogeneic bone marrow transplantation. Seventy-nine patients are evaluable for risk of relapse: 32 with chronic myelogenous leukemia (23 in first chronic phase, 9 in accelerated phase) and 47 with acute myeloid leukemia (38 in first complete remission, 9 in subsequent phases). Actual TBI doses delivered to these patients varied between 839 and 1250 cGy (mean 956 ± 101)/3 fr/3d, with dose rates between 2.7 and 7.25 cGy/min (mean 4.2 ± 1.8). Patients receiving high (>990 cGy) and low (4 cGy/min and -4, respectively) have been evaluated overall and stratified by type of leukemia and phase of disease. When the patients are considered altogether, high total dose is significantly correlated with decreased risk of relapse (p = 0.0005) as well as high dose rate (p = 0.03). When considering specific subgroups, the influence of total dose on relapse rate is evident both for "early" and "advanced" leukemias, while an impact of dose rate appears only for chronic myelogenous leukemia in 1st chronic phase. Pertinent radiobiological and clinical literature is reviewed, and a possible role of dose fractionation and dose rate in leukemic control rate is evidenced; in this TBI setting, total dose not less than 990 cGy/3fr/3d and dose rate not less than 4 cGy/min have to be guaranteed.
AB - From June 1981 to March 1987, 106 patients-59 with acute myeloid leukemia (AML) and 47 with chronic myelogenous leukemia (CML)-were treated with Cyclophosphamide 60 mg/kg X2 d and total body irradiation (TBI-990 cGy/3fr/3d described dose) before allogeneic bone marrow transplantation. Seventy-nine patients are evaluable for risk of relapse: 32 with chronic myelogenous leukemia (23 in first chronic phase, 9 in accelerated phase) and 47 with acute myeloid leukemia (38 in first complete remission, 9 in subsequent phases). Actual TBI doses delivered to these patients varied between 839 and 1250 cGy (mean 956 ± 101)/3 fr/3d, with dose rates between 2.7 and 7.25 cGy/min (mean 4.2 ± 1.8). Patients receiving high (>990 cGy) and low (4 cGy/min and -4, respectively) have been evaluated overall and stratified by type of leukemia and phase of disease. When the patients are considered altogether, high total dose is significantly correlated with decreased risk of relapse (p = 0.0005) as well as high dose rate (p = 0.03). When considering specific subgroups, the influence of total dose on relapse rate is evident both for "early" and "advanced" leukemias, while an impact of dose rate appears only for chronic myelogenous leukemia in 1st chronic phase. Pertinent radiobiological and clinical literature is reviewed, and a possible role of dose fractionation and dose rate in leukemic control rate is evidenced; in this TBI setting, total dose not less than 990 cGy/3fr/3d and dose rate not less than 4 cGy/min have to be guaranteed.
KW - Acute myeloid leukemia
KW - Chronic myelogenous leukemia
KW - Dose
KW - Dose rate
KW - Total body irradiation
UR - http://www.scopus.com/inward/record.url?scp=0024414802&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0024414802&partnerID=8YFLogxK
U2 - 10.1016/0360-3016(89)90105-3
DO - 10.1016/0360-3016(89)90105-3
M3 - Article
C2 - 2674077
AN - SCOPUS:0024414802
SN - 0360-3016
VL - 17
SP - 547
EP - 552
JO - International Journal of Radiation Oncology Biology Physics
JF - International Journal of Radiation Oncology Biology Physics
IS - 3
ER -